SCHEMBL2095985

SCHEMBL2095985

O=C1[C]C(=O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
CDC25B P30305 3/20 0.50
MAOA P21397 4/20 0.47
POLB P06746 3/20 0.47
S100A4 P26447 3/20 0.47
KDM4E B2RXH2 3/20 0.47
LMNA P02545 3/20 0.47
CES1 P23141 3/20 0.47
APAF1 O14727 2/20 0.47
TDP2 O95551 2/20 0.47
MAPK1 P28482 2/20 0.47
RECQL P46063 2/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
BLM P54132 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
BCHE P06276 2/20 0.47
CES2 O00748 1/20 0.47
TERT O14746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthraquinone SCHEMBL8081485 0.72 MEN1 (0.92) KMT2AMEN1CDC25BMAOAPOLB
SCHEMBL223194 0.69 IDO1 (0.48) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL14943 0.67 MEN1 (1.00) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL29358690 0.67 MEN1 (1.00) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL1901249 0.67 MEN1 (1.00) KMT2AMEN1CDC25BMAOAPOLB
SCHEMBL577831 0.67 CDC25B (0.58) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL6415478 0.65 MEN1 (0.92) KMT2AMEN1CDC25BMAOAPOLB
9,10-Phenanthrenequinone SCHEMBL43050 0.65 MEN1 (1.00) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL10991985 0.65 MEN1 (0.92) KMT2AMEN1CDC25BMAOAPOLB
Anthraquinone SCHEMBL10905960 0.65 MEN1 (0.92) KMT2AMEN1CDC25BMAOAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806989-B2 REDOX SYSTEM BETWEEN RADIATION TRANSPARENT PLATES BAYER AKTIENGESELLSCHAFT (DE) 2004-10-19 US claimed
US-20030129368-A1 Redox system between radiation transparent plates BAYER AKTIENGESELLSCHAFT (DE) 2003-07-10 US claimed
US-4983324-A NONLINEAR OPTICAL MATERIALS AND DISPLAY DEVICE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1991-01-08 US claimed
EP-0308444-A1 PYRROL 1.2-b]AZINES MERCK PATENT GmbH (DE) 1989-03-29 EP claimed
WO-1988007702-A1 PYRROL [1.2-b]AZINES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-10-06 WO claimed
EP-2851386-B1 RESIN COMPOSITION FOR OPTICAL STEREOLITHOGRAPHY CMET INC (JP) 2017-08-16 EP disclosed
EP-2851386-A1 RESIN COMPOSITION FOR OPTICAL STEREOLITHOGRAPHY Cmet Inc. (JP) 2015-03-25 EP disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 CN disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 CN disclosed
US-20030175616-A1 Optical recording media; high density writing LANXESS DEUTSCHLAND GMBH (DE) 2003-09-18 US disclosed
EP-1273006-A1 USE OF LIGHT-ABSORBING COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS, AND OPTICAL DATA CARRIERS Bayer Aktiengesellschaft (DE) 2003-01-08 EP disclosed
WO-2001075873-A1 USE OF LIGHT-ABSORBING COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS, AND OPTICAL DATA CARRIERS BAYER AKTIENGESELLSCHAFT (DE) 2001-10-11 WO disclosed
US-4983324-A NONLINEAR OPTICAL MATERIALS AND DISPLAY DEVICE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1991-01-08 US disclosed
EP-0308444-A1 PYRROL 1.2-b]AZINES MERCK PATENT GmbH (DE) 1989-03-29 EP disclosed
WO-1988007702-A1 PYRROL [1.2-b]AZINES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-10-06 WO disclosed
US-4358521-A ELECTROGRAPHY FUJI PHOTO FILM CO., LTD. (JP) 1982-11-09 US disclosed
US-4241154-A CHELATE COMPOUNDS, COLOR PHOTOGRAPHY FUJI PHOTO FILM CO., LTD. (JP) 1980-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KMT2A 3324/4885MEN1 4525/4885CDC25B 968/4885
US-20030175616-A1 Optical recording media; high density writing RHOA, IK, YTHDF1 KMT2A 165/4885MEN1 2318/4885CDC25B 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.